https://www.selleckchem.com/pr....oducts/3-deazaneplan
Background Low-density lipoprotein (LDL) levels are increased by proprotein convertase subtilisin kexin 9 (PCSK9) which targets the LDL receptor. We recently reported that PCSK9 ameliorates dendritic cell (DC) activation by oxidized LDL (OxLDL), which is abundant in atherosclerotic plaques and is also associated with cardiovascular disease (CVD) in systemic lupus erythematosus (SLE). Here, we investigated the role of PCSK9 in SLE. Methods PCSK9 levels were determined by ELISA among SLE patients (N = 109) and age- and s
Like
Comment
Share
